期刊
TRENDS IN PHARMACOLOGICAL SCIENCES
卷 30, 期 10, 页码 509-514出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2009.07.002
关键词
-
资金
- Medical Research Council of Great Britain
- Russian Academy of Sciences Programme
- MRC [G0501565, G9824728] Funding Source: UKRI
- Medical Research Council [G9824728, G0501565] Funding Source: researchfish
Sodium valproate, or Epilim, has been widely used as a broad spectrum, anticonvulsant drug for over 40 years and exhibits a good safety profile. Some of the actions of valproate arise from its more recently described histome deacetylase (HDAC) inhibitory properties and hence it can specifically modulate gene expression. There is now accumulating evidence that HDAC inhibitors may have potential in the treatment of CNS disorders and, in this context, valproate has much potential as a brain-penetrant, clinically available and well tested drug. This article reviews the pharmacology of this remarkable molecule, focusing on its actions as a neuroprotectant and hence with new potential in the treatment of neurodegenerative diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据